Tag:

Diabetes

Latest Headlines

Latest Headlines

Meta-analysis: Avandia's impact on Parkinson's should spur new research

A meta-analysis of data from more than 160,000 diabetics has offered some convincing data to support the theory that PPARγ activation by glitazones--either Avandia (GlaxoSmithKline's rosiglitazone) or pioglitazone--offers significant protection against Parkinson's disease. And the researchers who did the study say that their work should help accelerate work in the field.

Novo heralds promising PhIII diabetes data for once-weekly semaglutide

Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug--a key part of the pipeline--slashed HbA1c levels by 1.5% and 1.6%.

Israel's Oramed says $50M oral insulin deal with Sinopharm Capital-Hefei, not Guangxi Wuzhou

Israel's Oramed announced final-stage talks of a $50 million deal to sell China rights for its clinical-stage oral insulin candidate to a consortium of investors. The group consists of Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development.

China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus

China's Guangxi Wuzhou Pharmaceutical bought a 10% stake in Israel's Oramed Pharma for $52 million as well as China rights to two diabetes treatments, Reuters reported. The deal builds on a December 2014 investment of $5 million for a 7% stake in a private placement.

Survey: Hypertension, diabetes among key rising chronic diseases in China

Hypertension afflicted 25.2% of China's adult population and diabetes 9.7%, according to the state-run Xinhua news agency. That's according to a survey conducted by the National Health and Family Planning Commission over a decade that jibes with other recent public policy healthcare reform efforts by the State Council.

Report: Novo, Sanofi and Merck dominate global diabetes market

The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the pack, posting solid gains for their products as they compete for a piece of a rapidly growing market.

A heavier China drives cardio, diabetes and healthcare reforms

Rising cardiovascular disease rates in China are directly linked to a change in diet as incomes drive up demand for processed meat with high salt content. That and other dietary changes are creating a heavier population and driving government healthcare cost reforms, Xinhua reports.

UPDATED: AdverseEvents: Diabetes drug analysis flags heart failure, pancreatitis reports

Drugmakers are hot to trot after diabetes meds, and for good reason--the disease population is large, and growing. But the drugs have raised a few eyebrows lately, with regulators taking aim at safety issues tied to SGLT2 and DPP-4 drugs in particular. And SGLT2 and DPP-4 meds are not the only offenders, as side effect reports continue to mount for GLP-1 drugs.

Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say no

Some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it.

Panasonic Healthcare pays $1.15B for Bayer diabetes unit, beating Sinocare

KKR-backed Panasonic Healthcare clinched a deal to buy Bayer's Diabetes Care unit in months of dealmaking that saw sources suggest an offer range of $2.3 billion to $830 million and included a reported bid by China's Sinocare for $1 billion.